Global Patent Index - EP 2316447 A1

EP 2316447 A1 20110504 - Method of inhibiting remnant lipoprotein production

Title (en)

Method of inhibiting remnant lipoprotein production

Title (de)

Methoden zur Hemmung der Restlipoproteinproduktion

Title (fr)

Méthodes pour inhiber la production de lipoprotéines rémanents

Publication

EP 2316447 A1 20110504 (EN)

Application

EP 11153547 A 20040924

Priority

  • EP 04773516 A 20040924
  • JP 2003373453 A 20030926
  • US 59081104 P 20040723

Abstract (en)

The present invention aims at provision of a method for inhibiting remnant lipoprotein production and a remnant lipoprotein production inhibitor, which includes administering a compound having a CETP inhibitory activity to an administration subject. The remnant lipoprotein production inhibitor of the present invention contains a compound having a CETP inhibitory activity as an active ingredient.

IPC 8 full level

A61K 31/265 (2006.01); A61K 31/00 (2006.01); A61K 31/137 (2006.01); A61K 31/16 (2006.01); A61K 31/165 (2006.01); A61K 31/167 (2006.01); A61K 31/27 (2006.01); A61K 31/341 (2006.01); A61K 31/41 (2006.01); A61K 31/4196 (2006.01); A61K 31/47 (2006.01); A61P 3/06 (2006.01); A61P 9/10 (2006.01)

CPC (source: EP KR US)

A61K 31/00 (2013.01 - EP US); A61K 31/137 (2013.01 - EP US); A61K 31/16 (2013.01 - EP US); A61K 31/165 (2013.01 - EP US); A61K 31/167 (2013.01 - EP KR US); A61K 31/196 (2013.01 - EP US); A61K 31/255 (2013.01 - US); A61K 31/27 (2013.01 - EP US); A61K 31/277 (2013.01 - EP US); A61K 31/325 (2013.01 - EP US); A61K 31/41 (2013.01 - EP KR US); A61K 31/415 (2013.01 - EP US); A61K 31/4196 (2013.01 - EP US); A61K 31/42 (2013.01 - EP US); A61K 31/421 (2013.01 - EP US); A61K 31/4245 (2013.01 - EP US); A61K 31/425 (2013.01 - EP US); A61K 31/426 (2013.01 - EP US); A61K 31/433 (2013.01 - EP US); A61K 31/4402 (2013.01 - EP US); A61K 31/4406 (2013.01 - EP US); A61K 31/47 (2013.01 - EP KR US); A61K 31/506 (2013.01 - EP US); A61P 3/06 (2018.01 - EP); A61P 3/10 (2018.01 - EP); A61P 5/14 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 43/00 (2018.01 - EP)

Citation (applicant)

Citation (search report)

  • [X] EP 1020439 A1 20000719 - JAPAN TOBACCO INC [JP]
  • [X] SHINKAI HISASHI ET AL: "Bis[2-(Acylamino)phenyl] Disulfides, 2-(Acylamino)benzenethiols, and S-[2-(Acylamino)phenyl] Alkanethioates as Novel Inhibitors of Cholesteryl Ester Transfer Protein", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 2000, pages 3566 - 3572, XP002288180, ISSN: 0022-2623
  • [X] OKAMOTO H ET AL: "A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR ATTENUATES ATHEROSCLEROSIS IN RABBITS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 406, no. 6792, 2000, pages 203 - 207, XP002266120, ISSN: 0028-0836
  • [X] DE GROOTH GREETJE J ET AL: "The efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705", CIRCULATION, vol. 104, no. 17 Supplement, 23 October 2001 (2001-10-23), & SCIENTIFIC SESSIONS 2001 OF THE AMERICAN HEART ASSOCIATION; ANAHEIM, CALIFORNIA, USA; NOVEMBER 11-14, 2001, pages II.176, XP008042177, ISSN: 0009-7322
  • [X] GROOTH DE G J ET AL: "Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: A randomized phase II dose-response study", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 105, 2002, pages 2159 - 2165, XP002288183, ISSN: 0009-7322
  • [X] OKAMOTO HIROSHI ET AL: "Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals", EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 466, 2003, pages 147 - 154, XP002288185, ISSN: 0014-2999
  • [X] HUANG Z ET AL: "Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia", CLINICAL SCIENCE, BIOCHEMICAL SOCIETY AND THE MEDICAL RESEARCH SOCIETY, LONDON,, GB, vol. 103, 2002, pages 587 - 594, XP002288184, ISSN: 0143-5221
  • [A] HAVEL R J: "Remnant lipoproteins as therapeutic targets", CURRENT OPINION IN LIPIDOLOGY, LIPPINCOTT WILLIAMS AND WILKINS, LONDON, GB, vol. 11, no. 6, 1 December 2000 (2000-12-01), pages 615 - 620, XP008127814, ISSN: 0957-9672

Designated contracting state (EPC)

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)

AL HR LT LV MK

DOCDB simple family (publication)

WO 2005030185 A2 20050407; WO 2005030185 A3 20050811; AU 2004275637 A1 20050407; AU 2004275637 B2 20080717; AU 2004275637 C1 20101125; BR PI0414822 A 20061114; CA 2554982 A1 20050407; CN 101342162 A 20090114; CN 103330703 A 20131002; CN 1886124 A 20061227; CO 5690566 A2 20061031; EP 1670446 A2 20060621; EP 2316447 A1 20110504; EP 2319509 A1 20110511; IL 174310 A0 20060801; IL 174310 A 20110331; IL 193771 A0 20090504; IL 193771 A 20130930; JP 2007506646 A 20070322; JP 2010111696 A 20100520; JP 4536061 B2 20100901; JP 5214638 B2 20130619; KR 20060080214 A 20060707; KR 20070087197 A 20070827; MX PA06003357 A 20060608; NO 20061818 L 20060626; NZ 546732 A 20091030; NZ 569469 A 20100326; RU 2006114044 A 20071120; RU 2330682 C2 20080810; SG 146695 A1 20081030; US 2007054839 A1 20070308; US 2011189210 A1 20110804; US 2014364493 A1 20141211; ZA 200603280 B 20100526; ZA 200806375 B 20090729

DOCDB simple family (application)

JP 2004014428 W 20040924; AU 2004275637 A 20040924; BR PI0414822 A 20040924; CA 2554982 A 20040924; CN 200480034573 A 20040924; CN 200810107841 A 20040924; CN 201310227599 A 20040924; CO 06037892 A 20060421; EP 04773516 A 20040924; EP 11153508 A 20040924; EP 11153547 A 20040924; IL 17431006 A 20060314; IL 19377108 A 20080831; JP 2006515401 A 20040924; JP 2010004396 A 20100112; KR 20067005734 A 20060323; KR 20077016830 A 20070720; MX PA06003357 A 20040924; NO 20061818 A 20060425; NZ 54673204 A 20040924; NZ 56946904 A 20040924; RU 2006114044 A 20040924; SG 2008073645 A 20040924; US 201414155744 A 20140115; US 38954206 A 20060324; US 89037910 A 20100924; ZA 200603280 A 20060425; ZA 200806375 A 20060425